Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.51 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.51 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17335271 | 0.92 | PIK3CD (0.52) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17335496 | 0.90 | PIK3CD (0.51) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL15812940 | 0.87 | PIK3CD (0.53) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17334917 | 0.87 | PIK3R2 (0.49) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17334666 | 0.87 | PIK3CD (0.61) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17335399 | 0.85 | PIK3CD (0.51) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17335420 | 0.83 | PIK3CD (0.51) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17334919 | 0.83 | PIK3CD (0.54) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17334921 | 0.83 | PIK3CD (0.54) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17335462 | 0.82 | PIK3CD (0.41) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154961-B1 | QUINAZOLINONE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10308639-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20150361070-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361070-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, AKT2 | PIK3CD 4/4885PIK3R1 20/4885PIK3CB 9/4885 |
| US-10308639-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, AKT3, AKT2 | PIK3CD 4/4885PIK3R1 20/4885PIK3CB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.